BRIEF-Allergan research chief says Pfizer immuno-oncology pipeline underappreciated

Jan 12 (Reuters) -

* Pfizer says its experimental off-the-shelf CAR T cell therapies for cancer may have major advantages over personalized CAR T cells

* Allergan research chief says company’s drug pipeline is underappreciated

* Pfizer CEO says decision whether to split company to depend whether “trapped value” in the businesses is apparent in 2018

* Allergan research chief says depth of Pfizer’s immuno-oncology pipeline underappreciated Source text for Eikon: Further company coverage: (Reporting by Ransdell Pierson)